Dylan Beynon – Founder & CEO of Mindbloom

Dylan Beynon – Founder & CEO of Mindbloom

Dylan Beynon is the founder and CEO of Mindbloom, a healthcare company focused on expanding access to psychedelic medicine through clinician-guided, at-home ketamine therapy.

Founded in 2018, Mindbloom has built one of the largest at-home psychedelic therapy platforms in the United States. The company says it has facilitated more than 850,000 treatment sessions, operates across 36 states, and reaches approximately 84% of the U.S. population.

Beynon is a three-time founder whose earlier companies focused on civic engagement and access to justice. His first startup, Voter's Friend, was acquired by Democracy.com in 2014. He later co-founded Mighty, a company focused on helping people involved in civil-justice cases obtain financial support, before turning his attention to mental healthcare.

His decision to enter psychedelic healthcare was influenced by his family's experience with mental illness and addiction and by his own experience with psychedelic therapy. Beynon has said that these experiences led him to believe that psychedelic medicine could become a more accessible option for people who had not benefited sufficiently from conventional approaches.

Today, Beynon is leading Mindbloom as the company expands its clinical research, telehealth infrastructure, treatment formats, insurance and reimbursement options, and broader vision for psychedelic medicine.

Who Is Dylan Beynon?

Dylan Beynon is an entrepreneur known for building companies around problems involving access.

His career has followed a consistent pattern: identify a system that is difficult for ordinary people to navigate, use technology to simplify access, and build a business around making that system more accessible.

That philosophy appeared first in civic technology with Voter's Friend, then in legal finance with Mighty, and eventually in healthcare through Mindbloom.

Mindbloom represents the most ambitious stage of that approach because it operates at the intersection of healthcare, telemedicine, technology, behavioral health, and psychedelic medicine.

Mindbloom's current leadership page describes Beynon as a three-time founder, with one exit and two healthcare category leaders, and says his companies have collectively raised hundreds of millions of dollars. The company also notes that he received a full Trustee Scholarship at the University of Pennsylvania's Wharton School.

Education at Wharton

Beynon studied at the Wharton School of the University of Pennsylvania, where he earned a bachelor's degree in economics.

His academic background included entrepreneurship, decision theory, and consumer psychology, according to biographical profiles associated with his professional history.

He attended Wharton on a full Trustee Scholarship.

His combination of economics, consumer psychology, entrepreneurship, and technology became relevant to his later career, particularly in companies where customer behavior and accessibility were central to the business model.

Early Career and Hotlist

Before founding his own companies, Beynon worked as a product manager at Hotlist, an early technology company.

The experience gave him exposure to product development and growth before he began building companies himself.

His professional path subsequently moved toward startups where growth, technology, and access were central components.

Founding Voter's Friend

In 2012, Beynon co-founded Voter's Friend, a civic-technology company designed to make election information easier for voters to understand and navigate.

The company aggregated government and election data and used it to provide users with geographically relevant information about candidates, elections, and ballots.

According to Crunchbase's profile of Beynon, Voter's Friend grew into one of the larger election websites and applications in the country before being acquired by Democracy.com in 2014.

The acquisition was Beynon's first major startup exit.

It also established a recurring theme in his career: using technology to simplify complicated systems that ordinary consumers often find difficult to navigate.

Co-Founding Mighty

After Voter's Friend, Beynon co-founded Mighty, a company focused on helping people involved in civil-justice cases access financial resources.

He served as the company's Chief Growth Officer.

Mighty's business model was built around providing financing and other financial services to plaintiffs involved in legal claims.

The company raised more than $100 million, according to Beynon's biography on the Pod of Jake podcast.

The experience gave Beynon exposure to financial technology, healthcare-adjacent services, regulated industries, customer acquisition, and operating a larger venture-backed company.

He remained with Mighty until 2018.

Why Beynon Founded Mindbloom

Beynon's move into psychedelic medicine was highly personal.

Mindbloom's official account says his mother and sister experienced severe mental illness, addiction, and homelessness and both eventually died from overdoses. Beynon has publicly described how these experiences shaped his interest in finding better mental-health treatments.

He also says that psychedelic therapy had a major impact on his own life.

According to Mindbloom, Beynon first turned to psychedelic therapy in 2009 and later experienced ketamine therapy in 2018. He became convinced that existing access to psychedelic treatment was too expensive, difficult to navigate, and insufficiently supported.

That became the motivation for creating Mindbloom.

Rather than building a company around psychedelics as a lifestyle product, Beynon sought to build a structured healthcare platform combining medicine, clinicians, coaching, technology, and integration support.

Founding Mindbloom

Beynon founded Mindbloom in 2018.

The company's initial focus was guided, clinician-prescribed ketamine therapy delivered through telehealth.

The business model addressed several barriers associated with traditional ketamine clinics.

Instead of requiring patients to travel repeatedly to specialized clinics, Mindbloom developed an at-home model in which patients could receive treatment under a clinical framework with remote medical oversight.

Mindbloom's stated mission is to make next-generation mental-health treatments more approachable, affordable, and available.

Building an At-Home Ketamine Platform

At-home ketamine therapy became the foundation of Mindbloom's business.

The company combines several components:

• Medical evaluation

• Clinician oversight

• Prescribed ketamine

• At-home treatment

• Preparation and integration support

• Coaching

• Digital treatment programs

• Community support

• Treatment monitoring

This approach differentiates Mindbloom from businesses that primarily provide medication without an extensive support infrastructure.

Mindbloom's current pricing materials describe treatment programs that combine clinician consultations, guide coaching, medication, integration circles, digital content, and access to its app.

The Telehealth Advantage

Telehealth became particularly important to Mindbloom's growth.

Traditional ketamine treatment often required patients to travel to clinics for intravenous infusions.

Beynon's model was based on bringing the treatment experience into the patient's home while maintaining clinical oversight.

In January 2025, Mindbloom said that its at-home model had made ketamine therapy available to 86% of Americans and reduced treatment costs by approximately 80% compared with traditional clinic-based treatment. At that point, the company reported nearly 600,000 sessions across 38 states since 2019.

Mindbloom's latest website reports more than 850,000 sessions and availability across 36 states, reflecting subsequent changes in its operating footprint.

Mindbloom's Clinical Research

One of the most important elements of Beynon's strategy has been investing in clinical outcomes research.

Mindbloom has published large observational studies examining outcomes among its clients.

In a 2024 publication, the company reported results from 11,441 Mindbloom clients, describing it as the largest study of psychedelic medicine at that time.

The study reported that:

• 62% of clients experienced clinically significant improvements in depression or anxiety symptoms

• 28% achieved remission

• 84% of clients who experienced significant improvement initially maintained improvement or recovered in a subsequent round

• Fewer than 5% reported side effects

The research involved authors from institutions including Johns Hopkins and NYU. These are results reported from Mindbloom's observational client data and should not be interpreted as establishing that ketamine therapy is appropriate for every patient.

The company's earlier study of more than 1,200 clients reported that 89% experienced some improvement in depression or anxiety symptoms after four sessions.

AI and Mental Healthcare Research

Mindbloom has also incorporated artificial intelligence into its research efforts.

The company's 2024 study used AI-based analysis to identify factors that might predict treatment response, with the stated goal of giving clinicians additional information when supporting clients.

This illustrates an important aspect of Beynon's strategy.

Mindbloom is not positioned simply as a telehealth provider. It is attempting to combine healthcare delivery, clinical research, behavioral data, and software.

That combination could allow the company to improve how treatment programs are personalized while generating additional evidence around psychedelic medicine.

Expanding Beyond a Single Treatment

Although ketamine remains Mindbloom's primary treatment, Beynon has consistently described the company's mission more broadly.

The long-term vision is to build a platform around psychedelic medicine rather than around a single molecule.

Mindbloom has published material about the potential future use of other psychedelic-assisted treatments, including MDMA-assisted therapy.

Beynon has publicly expressed strong interest in the future of psychedelic medicine and has argued that emerging therapies could create new options for people who have not responded adequately to conventional treatments.

The company's strategy therefore depends partly on the evolution of medical research and U.S. regulatory policy.

The Regulatory Environment

Psychedelic healthcare operates within a complicated regulatory environment.

Ketamine is legally available by prescription in the United States, but it is important to distinguish that from FDA approval for specific psychiatric indications.

Mindbloom itself states that ketamine is not FDA-approved for the treatment of depression or anxiety and that its psychiatric use in this context is off-label.

This distinction is important when describing Mindbloom.

The company provides clinician-prescribed treatment under medical supervision, but its use of ketamine for depression and anxiety should not be presented as an FDA-approved indication.

The broader psychedelic sector also depends heavily on future clinical research and regulatory decisions concerning substances such as MDMA and psilocybin.

Mindbloom's Business Model

Mindbloom operates a consumer healthcare model that combines medical services with technology and ongoing support.

Current programs include:

• Clinician consultations

• Prescribed medication

• Guided treatment sessions

• One-on-one coaching

• Unlimited messaging with guides

• Group integration circles

• Digital programs

• The Mindbloom app

• Personalized treatment options

The company currently offers both sublingual ketamine tablets and subcutaneous injectable ketamine options.

The model allows Mindbloom to generate revenue from treatment programs rather than simply selling a pharmaceutical product.

That distinction is important to the company's strategy.

Its value proposition is the combination of medicine and an organized support system.

Making Treatment More Accessible

Accessibility has been a recurring theme throughout Beynon's career.

At Voter's Friend, he worked on making government and election information easier for consumers to navigate.

At Mighty, he focused on improving access to financial resources within the civil-justice system.

At Mindbloom, the problem became access to mental-health treatment.

The common thread is not a particular technology.

It is the attempt to reduce friction in systems that traditionally require significant time, money, expertise, or institutional access.

That philosophy helps explain why telehealth became such an important component of Mindbloom.

Mindbloom's Growth

Mindbloom has grown significantly since its founding.

The company says it has now facilitated more than 850,000 sessions and operates in 36 states. It describes itself as the largest national provider of at-home psychedelic therapy.

In 2025, Mindbloom reported having facilitated nearly 600,000 sessions and reaching 86% of Americans across 38 states.

The changing figures reflect the company's expansion as well as changes in state availability.

Mindbloom's current site also describes the company as having a remote-first culture dating back to its founding in 2018.

A Remote-First Healthcare Company

Mindbloom's operating model is unusual because it combines healthcare with a technology-company structure.

The company describes itself as remote-first from its founding.

Its current leadership team includes medical, financial, government-relations, growth, and technology-oriented roles.

Mindbloom also emphasizes written communication, asynchronous work, and deep work as part of its internal operating philosophy.

This reflects Beynon's background as a technology entrepreneur.

Rather than treating healthcare as a traditional clinic business, he has attempted to build Mindbloom as a technology-enabled healthcare platform.

Culture and Leadership Philosophy

Mindbloom's stated company values provide insight into Beynon's approach to leadership.

The company emphasizes:

Intellectual Honesty

Mindbloom asks employees to communicate directly, operate transparently, and use positive intent when giving feedback.

Exceptional Decisions

The company emphasizes concise writing, data, speed, and customer focus.

Wholeness

Mindbloom encourages employees to bring their authentic selves to work and emphasizes personal development.

Focus

The company promotes simplification, deep work, and the willingness to say no.

These principles are particularly relevant for a company operating in a new and rapidly evolving healthcare category.

Conscious Leadership

Beynon has also placed significant emphasis on company culture.

Mindbloom describes its leadership model as conscious leadership, with practices including regular 360-degree feedback, direct communication, and explicit commitments.

The company has also highlighted retreats and group activities involving strategy, AI, and integration sessions.

This focus on culture reflects Beynon's earlier experience building Mighty.

His work has therefore involved not only product and growth strategy but also designing organizational cultures around mission-driven companies.

Dylan Beynon's Writing and Public Advocacy

Beynon has become an active public advocate for psychedelic medicine.

In 2024, he launched The Psychedelic Optimist, a publication through which he writes about mental healthcare, psychedelic research, and his experiences as a founder and patient.

His writing combines personal experiences with arguments about healthcare access and the future of psychedelic medicine.

This public communication has become part of his role as CEO.

Rather than keeping Mindbloom's mission primarily within the company, Beynon has used writing, podcasts, interviews, and public appearances to advocate for broader acceptance and access to psychedelic therapies.

The Challenge of Building a New Healthcare Category

Beynon is building Mindbloom in a sector that is still developing.

The company must navigate several challenges simultaneously:

• Medical safety

• Clinical evidence

• Regulation

• State-by-state healthcare rules

• Patient trust

• Insurance reimbursement

• Public perception

• Pharmaceutical logistics

• Telehealth operations

• Responsible psychedelic use

That makes Mindbloom different from a conventional consumer software startup.

A product can be improved through rapid iteration, but healthcare businesses must also account for clinical evidence, medical oversight, regulatory requirements, and patient safety.

The Matthew Perry Media Controversy

Mindbloom also became involved in a high-profile media dispute in 2025.

Following reporting related to actor Matthew Perry's death, Mindbloom filed an $88 million defamation lawsuit against Dow Jones & Company, alleging that a Wall Street Journal headline falsely associated Mindbloom with Perry's death.

Mindbloom stated that Perry was never a Mindbloom client and argued that the reporting distorted the company's role and client experiences. Those allegations are claims made by Mindbloom in its lawsuit and should not be treated as adjudicated facts.

The dispute illustrates one of the challenges facing Beynon's company: psychedelic medicine remains a highly scrutinized field in which public perception can be shaped rapidly by individual incidents and media coverage.

Dylan Beynon as a Three-Time Founder

Beynon's career is notable for its progression across three very different categories.

Voter's Friend

Industry: Civic technology

Outcome: Acquired by Democracy.com in 2014

The company focused on making election information more accessible to voters.

Mighty

Industry: Legal finance / financial technology

Role: Co-Founder & Chief Growth Officer

Capital raised: More than $100 million

Mighty focused on financial access for people involved in civil-justice cases.

Mindbloom

Industry: Mental healthcare / psychedelic medicine

Role: Founder & CEO

Founded: 2018

Mindbloom represents Beynon's transition from access-focused technology businesses into healthcare.

What Makes Beynon's Entrepreneurial Approach Distinctive?

Beynon's companies share several characteristics.

First, each addresses a problem involving access.

Second, each uses technology to reduce friction.

Third, each operates in a sector where consumers often struggle to navigate complicated systems.

And fourth, Beynon tends to position the company around a broader social mission rather than simply a software product.

At Mindbloom, those characteristics have become particularly visible.

The company is simultaneously building a healthcare service, a technology platform, a research program, and a new category of consumer mental-health treatment.

Mindbloom's Current Product Direction

By 2026, Mindbloom has expanded beyond a simple telehealth prescription model.

Its programs combine medicine with coaching, clinical oversight, digital content, community, and ongoing support.

The company also offers both tablet and injectable ketamine treatment.

Mindbloom's current pricing page lists treatment programs ranging from six to 18 sessions, with pricing dependent on program length and client status.

The company has also introduced a 60-day refund policy for eligible purchases in participating states, although the policy explicitly states that it is a payment policy rather than a promise of clinical results.

The Role of Technology

Technology is central to Mindbloom's operating model.

The company's app provides access to treatment programs and content, while digital communications allow clients to interact with guides and the broader Mindbloom community.

AI has also entered the company's research process.

This creates a model in which technology supports several layers of the patient journey without replacing the clinician.

Mindbloom's current website explicitly describes its service as involving clinician-led care and notes that its affiliated psychiatric medical practices are independently owned and operated.

Dylan Beynon's Vision for Psychedelic Medicine

Beynon's long-term vision extends beyond ketamine.

He has argued that psychedelic medicine could eventually provide new treatment options for conditions including depression, addiction, PTSD, and other forms of mental-health difficulty.

His public writing has emphasized the possibility of combining emerging medicines with structured preparation, clinical oversight, and integration support.

The underlying idea is that the medicine itself is only one component of a broader therapeutic experience.

This explains why Mindbloom has invested in coaching, digital programs, community, and clinical research alongside medication delivery.

The Future of Mindbloom

Mindbloom's next stage will depend on several developments.

The company needs to continue demonstrating strong clinical outcomes while expanding access.

It must also navigate regulation as psychedelic medicine evolves.

At the same time, it has opportunities to expand its treatment platform, use AI to improve personalization and clinical decision support, develop additional treatment pathways, and potentially work with insurers and employers.

Mindbloom's current leadership materials describe the company as "extremely well-capitalized by Tier 1 VCs," although the company does not currently disclose a comprehensive public funding figure on its website.

For CEO Watch, it is therefore more accurate to describe Mindbloom as venture-backed and well-capitalized than to state an unverified total funding amount.

Why Dylan Beynon Matters in Healthcare Technology

Dylan Beynon represents a generation of entrepreneurs attempting to bring Silicon Valley-style product development and growth thinking into healthcare.

His career began in civic technology, moved through legal finance, and eventually reached mental healthcare.

At Mindbloom, he is tackling a particularly difficult problem: how to make an emerging medical treatment accessible to large numbers of people while maintaining clinical oversight and building evidence around outcomes.

The company has already reached substantial scale by its own reported measures, with more than 850,000 sessions facilitated and availability across 36 states.

Whether psychedelic medicine ultimately becomes a mainstream component of mental healthcare will depend on clinical research, regulation, medical practice, patient demand, and reimbursement.

Beynon's work places him directly at the center of that emerging industry.

Key Facts About Dylan Beynon

Category	Details
Full Name	Dylan Beynon
Current Role	Founder & CEO
Company	Mindbloom
Founded Mindbloom	2018
Industry	Mental Healthcare / Psychedelic Medicine / Telehealth
Education	University of Pennsylvania, Wharton School
Degree	B.S. in Economics
Scholarship	Trustee Scholarship
Previous Company	Mighty
Previous Role	Co-Founder & Chief Growth Officer, Mighty
Earlier Startup	Voter's Friend
Voter's Friend Outcome	Acquired by Democracy.com in 2014
Mindbloom Sessions	850,000+ reported
Current Coverage	36 U.S. states
Core Treatment	Clinician-guided at-home ketamine therapy
Treatment Formats	Sublingual tablets and subcutaneous injections
Research	Studies involving 1,200+ and 11,441 Mindbloom clients
Current Focus	Access, clinical outcomes, AI, psychedelic medicine
Book / Publication	The Psychedelic Optimist newsletter

Company scale and leadership information are based primarily on Mindbloom's current public materials; historical career information is supported by Crunchbase and public interviews.

Summary

Dylan Beynon is the founder and CEO of Mindbloom, a healthcare company focused on making psychedelic medicine more accessible through clinician-guided, at-home ketamine therapy.

A graduate of the Wharton School at the University of Pennsylvania, Beynon began his entrepreneurial career in civic technology. He co-founded Voter's Friend, a platform designed to simplify access to election information, which was acquired by Democracy.com in 2014.

He later co-founded Mighty, where he served as Chief Growth Officer. The company raised more than $100 million and focused on improving financial access for people involved in civil-justice cases.

In 2018, Beynon founded Mindbloom.

His motivation was deeply connected to his family's experience with mental illness and addiction and his own experiences with psychedelic therapy. He believed that emerging treatments could potentially help people who had not found sufficient benefit from conventional approaches, but that access remained too expensive and difficult.

Mindbloom's solution was to combine telehealth, clinician oversight, prescribed ketamine, coaching, digital tools, and community support.

The company has since grown into one of the largest at-home psychedelic therapy platforms in the United States. Mindbloom currently reports more than 850,000 facilitated sessions and availability across 36 states.

Beynon has also emphasized clinical evidence. Mindbloom's published research includes a 2024 observational study involving 11,441 clients, which reported clinically significant improvements and remission among portions of the participants.

At the same time, the company operates in a medically and legally sensitive field. Mindbloom itself notes that ketamine is not FDA-approved for treating depression or anxiety, making accurate communication about the treatment's regulatory status particularly important.

As Mindbloom continues to expand its clinical research, technology, treatment options, and geographic reach, Dylan Beynon remains one of the entrepreneurs most closely associated with the emerging psychedelic-medicine industry.